CRYAB promoter polymorphisms: influence on multiple sclerosis susceptibility and clinical presentation
Birgitte Stoevring1, Jette L Frederiksen, Michael Christiansen
1Department of Clinical Biochemistry, Statens Serum Institut, 5 Artillerivej, DK 2300 S, Copenhagen, Denmark.
Summary
Genetic variations in the alphaB-crystallin gene (CRYAB) are linked to multiple sclerosis (MS) susceptibility and disease progression. These CRYAB polymorphisms may influence MS pathogenesis by affecting alphaB-crystallin expression and immune response.
Area of Science:
- Neuroimmunology
- Genetics
- Molecular Biology
Background:
- AlphaB-crystallin, a molecular chaperone, is implicated in multiple sclerosis (MS) pathogenesis.
- Single nucleotide polymorphisms (SNPs) in the alphaB-crystallin gene (CRYAB) have been associated with MS susceptibility and disease course.
Purpose of the Study:
- To investigate mutations and polymorphisms within the CRYAB gene in MS patients.
- To determine the association of CRYAB genetic variations with MS clinical phenotypes.
Main Methods:
- Screening of the CRYAB gene for mutations in 233 MS patients and 96 controls.
- Analysis of coding and untranslated regions using Single Strand Conformation Polymorphism (SSCP) and DNA sequencing.
- Genotyping of identified SNPs (g.CRYAB-249C>G, g.CRYAB-650C>G, g.CRYAB-652A>G, g.CRYAB.2398T>G).
Main Results:
- No mutations were found in CRYAB; however, several SNPs were identified in promoter and intronic regions.
- The g.CRYAB-249C>G polymorphism showed significant genotype and allele distribution differences between MS subtypes (RRMS, SPMS) and controls.
- The g.CRYAB-249GG genotype was tentatively associated with earlier onset and slower progression in RRMS and SPMS patients.
Conclusions:
- CRYAB polymorphisms may contribute to MS pathogenesis through altered alphaB-crystallin expression and immune modulation.
- Further research incorporating CRYAB polymorphisms in multivariate biomarker studies for MS is recommended.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...